Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect Study of Duvelisib in Healthy Subjects
NCT02307461Phase 1Completed
- Sponsor
- Secura Bio
- Start
- Nov 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of duvelisib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and follicular lymphoma (FL) (3 cohorts), sponsored by Secura Bio. Primary endpoints: Assessment of bioequivalence of the IPI-145 test and reference formulations at 24 hours, Pharmacokinetic Parameter (AUClast) of IPI-145 at 24 hours and 2 more. Started Nov 2014; status: completed.
02
Drugs
duvelisib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02307461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307461.